Clinical trials: Apixaban
Venous Thromboembolism, Cancer
Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients
Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased…
- Trial name
- AVERT (NCT02048865)
- Testing
- Apixaban
- Where
- 14 sites in Canada
- Volunteers
- 575 people
- Sponsor
- Ottawa Hospital Research Institute
Atrial Fibrillation
Anticoagulation Preference by AF Patients Study
The main research question of this patient survey is to assess AF (Atrial Fibrillation) patients' preferences associated with different attributes which describe the different available anticoagulation treatment options (Vitamin…
- Trial name
- PRiSMA-AF (NCT02607371)
- Testing
- VKAs, NOACs including Rivaroxaban (Xarelto, BAY59-7939), Edoxaban
- Where
- Switzerland
- Volunteers
- 198 people
- Sponsor
- Bayer
Venous Thromboembolism
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants
The primary objective of the study is to evaluate the efficacy of REGN9933 for the prevention of venous thromboembolism (VTE) after unilateral total knee arthroplasty (TKA), compared to enoxaparin The secondary objectives of the…
- Trial name
- NCT05618808
- Testing
- REGN9933, Enoxaparin, Apixiban
- Where
- 16 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 373 people
- Sponsor
- Regeneron Pharmaceuticals
Ischemic Stroke, Patent Foramen Ovale
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
A registry of patients from the Asia-Pacific region with PFO and ischemic stroke, designed to study the characteristics, investigations, treatment and outcomes using real-world data.
- Trial name
- PACIFIC-PFO (NCT06983795)
- Testing
- PFO closure using approved PFO closure devices, Surgical PFO closure, Medical management
- Where
- Singapore
- Volunteers
- 1,000 people
- Sponsor
- National University Hospital, Singapore
Hemorrhage, Thromboembolism
Apixaban Discontinuation Prior to Major Surgery
The ADIOS study is a prospective, observational study will evaluate one hundred and thirty (130) patients with non-valvular atrial fibrillation who are currently receiving treatment with apixaban as indicated to reduce the risk…
- Trial name
- ADIOS (NCT02935751)
- Testing
- Lab tests for plasma levels of apixaban and anti-10a factor
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Thomas Jefferson University
Atrial Fibrillation, Periodontal Disease
Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
The purpose of this study is to evaluate the safety of a protocol which does not suspend the new oral anticoagulants (dabigatran, rivaroxaban and apixaban) in front of dental extractions in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Periodontal Disease, Hemorrhage
- Trial name
- NCT03181386
- Testing
- Rivaroxaban, Dabigatran and Apixaban, Warfarin
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Expanded Access for Apixaban
This is an expanded access designed to provide access to apixaban for eligible participants.
- Trial name
- NCT05187286
- Testing
- Apixaban
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Left Ventricular Thrombus
Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial
The investigators aimed to design this randomized control trial to compare rivaroxaban and apixaban with warfarin in Left ventricular thrombus resolution by Success rate of left ventricular thrombus resolution on follow up…
- Trial name
- WRAP (NCT05973188)
- Testing
- Warfarin, Rivaroxaban 20 MG Oral Tablet, Apixaban 5mg or 2.5mg oral tablet
- Where
- Pakistan
- Volunteers
- 141 people
- Sponsor
- Peshawar Institute of Cardiology
Atrial Fibrillation, Acute Coronary Syndrome
Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation
Atrial fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated and fast atrial activity, and coronary artery disease (chronic and acute coronary syndrome) is characterized by a generally atheromatous…
- Conditions
- Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis, Hemorrhage
- Trial name
- FACOREV (NCT05068414)
- Testing
- Blood panel
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Venous Thromboembolism, Bleeding
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral factor Xa inhibitor apixaban…
- Trial name
- ARTS (NCT06523959)
- Testing
- Apixaban 2.5 MG
- Where
- Finland
- Volunteers
- 5,436 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
Anticoagulation
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).
- Trial name
- NCT02640222
- Testing
- VKA, Apixaban, dabigatran
- Where
- France
- Volunteers
- 321,501 people
- Sponsor
- Bristol-Myers Squibb
Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET)
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Myeloproliferative neoplasms (MPNs) are blood disorders that occur when the body makes too many white or red blood cells, or platelets.
- Conditions
- Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET), JAK2 Mutation, Polycythemia Vera (PV)
- Trial name
- AIRPORT-MPN (NCT04243122)
- Testing
- Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Ottawa Hospital Research Institute
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster) along with standard anticoagulant therapy as…
- Conditions
- Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive
- Trial name
- SAFE-LYSE (NCT03988842)
- Testing
- Alteplase, Unfractionated heparin, Apixaban
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Victor Tapson, MD
Thromboprophylaxis
Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment
The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments.
- Trial name
- THROMBO-STOP (NCT07160686)
- Testing
- Apixaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 1,456 people
- Sponsor
- University of Birmingham
Ischemic Stroke, Anticoagulant Adverse Reaction
Evaluataion of NOAC Levels in Acute Stroke
Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over warfarin in preventing stroke and thromboembolism among patients with atrial fibrillation (AF) in several guidelines.
- Trial name
- NCT06144866
- Testing
- Dabigatran, rivaroxaban, apixaban, edoxaban
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- National Taiwan University Hospital
Drug Drug Interaction (DDI)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
- Trial name
- NCT07265466
- Testing
- JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Thrombosis, Injury Leg
Thromboprophylaxis in Lower Limb Immobilisation
The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.
- Trial name
- TiLLI (NCT06370273)
- Testing
- Rivaroxaban, Apixaban, Enoxaparin Injectable Solution
- Where
- 5 sites in United Kingdom
- Volunteers
- 10,044 people
- Sponsor
- Queen Mary University of London
Pulmonary Embolism (PE), Pulmonary Thromboembolism
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
A study based on a chart review of participants that presented with a sudden blood clot in the lung
- Trial name
- NCT03595891
- Testing
- Non-Interventional
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- Bristol-Myers Squibb
Thrombosis
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
Apixaban is an anticoagulant (also known as blood thinner) approved by the Food and Drug Administration (FDA) for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
- Trial name
- 4PAR (NCT02270918)
- Testing
- Kcentra, Apixaban
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Gynecologic Cancer, Venous Thromboembolism
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
The study will evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to…
- Trial name
- NCT02366871
- Testing
- Oral apixaban, Subcutaneous enoxaparin
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Colorado, Denver